Tokyo-based Edogawa Hospital has purchased an MRIdian system from ViewRay. A MRI-guided radiation therapy system, MRIdian amalgamates MR technology with cobalt radiation delivery and enables clinicians to visualize and adjust dose in real time.
It also allows clinicians to see soft tissue—which will be a major boon to Edogawa Hospital’s radiation therapy operations, says hospital president Shojiro Katoh, MD. “We believe MRIdian offers a new approach to cancer treatment through its ability to visualize the tumor and nearby anatomy in real-time and adapt the treatment based on that information,” Katoh says.
Yukihiro Hama, MD, PhD, chairman of Edogawa Hospital’s radiology department, also praised the technology, stating: “The ability to spare healthy tissue and focus dose more accurately through MRI-guidance is a significant advancement. We believe MRIdian is a vital addition to our radiation oncology offerings”
In mid-August, ViewRay announced that the company had received Shonin approval from the Japanese Ministry of Health, Labor and Welfare to market the MRIdian system within Japan—and, in September, the company announced the first sale in Japan to the National Cancer Center (NCC). Installation of the MRIdian system at NCC is currently underway, and patient treatments are expected to begin in the first half of 2017.
For more information regarding the MRIdian system, visit ViewRay.
